Media headlines about Thermo Fisher Scientific (NYSE:TMO) have been trending somewhat positive on Monday, Accern reports. Accern ranks the sentiment of press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Thermo Fisher Scientific earned a news impact score of 0.18 on Accern’s scale. Accern also assigned news stories about the medical research company an impact score of 46.4250330426191 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Here are some of the media headlines that may have impacted Accern Sentiment Analysis’s analysis:

Several research analysts recently commented on the stock. Bank of America Corporation reaffirmed a “buy” rating and issued a $210.00 price objective (up from $200.00) on shares of Thermo Fisher Scientific in a report on Friday, July 21st. Barclays PLC reaffirmed an “overweight” rating and issued a $200.00 price objective (up from $190.00) on shares of Thermo Fisher Scientific in a report on Monday, July 17th. Cleveland Research raised shares of Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a report on Thursday, July 20th. Wells Fargo & Company reaffirmed an “outperform” rating and issued a $200.00 price objective (up from $195.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 13th. Finally, Citigroup Inc. reaffirmed a “buy” rating and issued a $201.00 price objective (up from $182.00) on shares of Thermo Fisher Scientific in a report on Monday, July 10th. One analyst has rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $188.56.

Shares of Thermo Fisher Scientific (NYSE TMO) traded up 0.46% on Monday, reaching $174.03. 1,182,391 shares of the company’s stock traded hands. Thermo Fisher Scientific has a 52-week low of $139.07 and a 52-week high of $182.87. The stock has a market cap of $67.89 billion, a price-to-earnings ratio of 30.32 and a beta of 1.06. The firm’s 50-day moving average is $176.77 and its 200-day moving average is $166.03.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, July 26th. The medical research company reported $2.30 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.27 by $0.03. The firm had revenue of $5 billion during the quarter, compared to analysts’ expectations of $4.92 billion. Thermo Fisher Scientific had a net margin of 11.80% and a return on equity of 15.97%. The company’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period in the prior year, the company posted $2.03 earnings per share. Analysts anticipate that Thermo Fisher Scientific will post $9.24 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, October 16th. Stockholders of record on Friday, September 15th will be paid a $0.15 dividend. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.34%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.45%.

In related news, CFO Stephen Williamson sold 2,500 shares of the company’s stock in a transaction on Monday, June 5th. The shares were sold at an average price of $176.26, for a total transaction of $440,650.00. Following the completion of the transaction, the chief financial officer now owns 37,790 shares in the company, valued at $6,660,865.40. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Marc N. Casper sold 20,000 shares of the company’s stock in a transaction on Thursday, June 1st. The stock was sold at an average price of $172.79, for a total transaction of $3,455,800.00. Following the transaction, the chief executive officer now owns 269,279 shares of the company’s stock, valued at approximately $46,528,718.41. The disclosure for this sale can be found here. Over the last three months, insiders sold 27,188 shares of company stock valued at $4,702,223. Corporate insiders own 0.49% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece was first published by Watch List News and is the property of of Watch List News. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The correct version of this piece can be accessed at https://www.watchlistnews.com/thermo-fisher-scientific-nysetmo-given-media-sentiment-rating-of-0-18/1488031.html.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Insider Buying and Selling by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.